Sanofi Counts On OTC Switches Adding $1bn In Consumer Revenues By 2026
Executive Summary
Sanofi eyes $1bn top line growth from OTC switches of ED drug Cialis and flu drug Tamiflu after they launch by 2026, says CEO Paul Hudson. Like switch consultants, though, he acknowledges the high bar for approval moving additional Rx ingredients to OTC.
You may also be interested in...
Euro Q1 Consumer Health Earnings Preview: Sanofi, Reckitt, GSK And Bayer
Major Europe-based consumer health players Sanofi, Reckitt, GSK and Bayer feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q1 2022 results over the coming weeks.
Poland’s Adamed Secures Tadalafil Rx-To-OTC Switch In World First
Poland becomes the first country in the world to allow erectile dysfunction treatment tadalafil to be bought without a prescription thanks to a successful Rx-to-OTC switch application from local player Adamed Pharma.
Sanofi Not Distracted By M&A Chatter As It Gets Back On Par With Market Growth
Recent market interest shown in other OTC assets will not distract Sanofi from its long-term plan to overhaul its Consumer Healthcare business, says CEO Paul Hudson. And this plan is delivering results, with Sanofi back on par with the consumer health market, posting sales up by 5% in 2021.